All News
Lower Income Elderly are More Likely to Use Opioids
The Journal of Gerontology reports that the poorest of the elderly are the most likely to receive prescription opioids.
Read Article
BMS Tyk 2 Inhibitor Benefits Psoriasis
The NEJM reports that an oral selecive Tyrosine kinase 2 (TYK2) inhibitor of TYK2 was shown to be superior to placebo in a 12 week trial in patients with active psoriasis.
Read Article
Out of Pocket Costs for Biosimilars - No Savings So Far
JAMA has published an analysis showing that under Medicare Part D, RA biosimilar infliximab-dyyb was only moderately less expensive (18% less) than the biologic infliximab and, owing to differences in gap discounts, the out of pocket costs for the biosimilar was nearly $1700 more than infliximab
Read Article
Cutting Oral JAK 1/2 Inhibitor Dose an Option in RA
Many patients with rheumatoid arthritis (RA) who achieved sustained disease control with baricitinib (Olumiant) treatment were able to reduce their daily dose from 4 mg to 2 mg and maintain their response, a double-blind substudy of a long-term extension trial found.
Read Article
Physician Burnout May Jeopardize Patient Safety
A metanalysis of studies and over 42,000 physician shows that MD burnout is associated with 2-fold increased in unsafe care, unprofessional behaviors, and low patient satisfaction.
The primary outcomes were the quantitative associations between burnout and patient safety, professionalism, and patient satisfaction.
Methotrexate's Low Efficacy in Cutaneous Psoriasis
In a prospective, double-blind, randomized placebo-controlled study, Warren et al. studied the effect of an intensified methotrexate (MTX) in chronic plaque psoriasis and showed MTX to be effective and superior to placebo.
Read Article
Usual Allopurinol Doses Insufficient in CKD Patients
Uric acid (sUA) control may be a challenge in patients with chronic kidney disease (CKD). A cohort study shows that conventional dosing recommendations for allopurinol are unlikely to reach target serum sUA goals.
Read Article
Tocilizumab Equals other Biologics in Cardiovascular Risk
An odd side effect of several new agents is the risk of hyperlipidemia. While this has been seen with tocilizumab (TCZ), there does not appear to be a resultant risk of cardiovascular (CV) events. A study of claims data compared CV risk in rheumatoid arthritis (RA) patients receiving TOC (an IL6 receptor antagonists) and other biologics and found no differences with regard to CV outcomes.
Read Article
New BSR Guidelines on Biologic Safe Use with Inflammatory Arthritis
The British Society of Rheumatology has produced a set of NICE accredited guidelines for the use of biologic therapies in patients with inflammatory arthritis.
Read Article
No Cancer Risk from Psoriatic Arthritis
Inflammmation is a strong risk factor for malignancy. Yet there are mixed results on whether patients with psoriatic arthritis (PsAg) augments the incidence of cancer and all-cause and cause-mortality.
Read Article
2018 EULAR Recommendations for Hand Osteoarthritis Care
The European League Against Rheumatism (EULAR) has previously put forth recommendations for management of hand osteoarthritis (OA) in 2007. But since then, advances and further evidence have emerged.
Read Article
The Safety of Paternal Exposure to DMARDs and Biologics
Pregnancy and drug safety is a complex issue, often with limited informatoin about maternal drug exposure on the offspring. Greater uncertainty exists when considering whether paternal exposure may also influence fetal outcomes.
Read ArticleQuestions Remain about Shingrix Safety in Rheumatic Disease
The efficacy and safety of the new zoster vaccine Shingrix has not been established among patients with autoimmune diseases, researchers reported here.
Read Article
2018-2019 ACIP Recommendations for Seasonal Influenza Vaccination
The current issue of the CDC's MMWR reviews the new seasonal recommendations for vaccination against influenza. This is an update to the previous recommendations of the Advisory Committee on Immunization Practices (ACIP).
Read Article
RheumNow Week in Review – How Not to Treat Hand OA (8.24.18)
Dr. Jack Cush comments on the last week's news and journal highlights on RheumNow.com.
Read Article
Treatments Do Not Increase Infection Risk in Ankylosing Spondylitis
A large Canadian study of the drug use in ankylosing spondylitis (AS) demonstrated no evidence that the risk of serious, hospitalized infection was influenced by the use of DMARD and/or of tumour necrosis factor inhibitors (TNFi) therapy.
Read Article
Dietary Recommendations for Psoriatic Disease
A systematic review by the Medical Board of the National Psoriasis Foundation examined the role of diet in managing adult patients with psoriasis and/or psoriatic arthritis and suggest that dietary interventions to reduce disease severity.
Read Article
Health Secretary Azar Eyes Rebate Reform
Reuters reports that the U.S. Health and Human Services Secretary Alex Azar had declared his agency has the authority to eliminate rebates on prescription drug purchases, a key element in the administration’s plan to lower prescription medicine costs.
Read Article
ACR Meets With HHS Secretary Azar to Discuss Step Therapy Concerns
Yesterday, the American College of Rheumatology (ACR) met with U.S.
Read Article
The RheumNow Week in Review – We’re Number One! (8.17.18)
Dr. Cush reviews the articles and news from the last week on RheumNow.com. Information on comorbidities, the downside of steroids, unmet need in psoriatic arthritis, and the top 10 rheumatology programs.
Read Article
